作者:Gebhard Thoma、Siem Veenstra、Ross Strang、Joachim Blanz、Eric Vangrevelinghe、Jörg Berghausen、Christian C. Lee、Hans-Günter Zerwes
DOI:10.1016/j.bmcl.2015.08.037
日期:2015.10
Design and optimization of benzo- and pyrido-thiazoles/isothiazoles are reported leading to the discovery of the potent, orally bioavailable Syk inhibitor 5, which was found to be active in a rat PK/PD model. Compound 5 showed acceptable overall kinase selectivity. However, in addition to Syk it also inhibited Aurora kinase in enzymatic and cellular settings leading to findings in the micronucleus assay. As a consequence, compound 5 was not further pursued. (C) 2015 Elsevier Ltd. All rights reserved.